Explain this page
Arphra AIPlain-English read on Johnson & Johnson’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.16% | -3.46% | -0.43% | -8.99% | +10.25% | +7.87% | +45.70% | +41.01% | +34.51% | +92.83% | +18198.36% |
Aftermarket
LiveLast trade
$225.94
959 sh
Bid
$225.00
10 sh
Ask
$226.00
1 sh
Spread
$1.000
Sector & industry today
LiveSectors
- Healthcare+1.32%
- Financial Services+1.14%
- Industrials+0.68%
- Consumer Cyclical+0.59%
- Energy+0.52%
- Real Estate+0.46%
- Consumer Defensive+0.12%
- Basic Materials-0.28%
- Utilities-1.42%
- Communication Services-1.84%
- Technology-2.36%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General+1.84%
- Rental & Leasing Services+5.32%
- Financial - Mortgages-4.41%
- Broadcasting-4.23%
- Investment - Banking & Investment Services-4.21%
- Software - Application-4.13%
- Auto - Recreational Vehicles+4.13%
- Software - Infrastructure-3.47%
- Information Technology Services-3.40%
- Department Stores+3.03%
- Silver-3.02%
- Apparel - Retail+2.95%
Fair value
Football field →Weighted blend
$284.62
+27.50% vs spot
Recommendation
Strong Buy
18 of 19 methods
Method spread
6bull12bear
±5% threshold
Analyst PT consensus: $249.27 (+11.66%)
Total assets
$199.21B
Total debt
$47.93B
Cash & equiv
$19.71B
Operating CF
$24.53B
Free cash flow
$19.7B
Buybacks
-$5.95B
Analyst view
DB · price_targets + analyst_gradesConsensus target
$249.27
+11.66% upside
Low
$208.00
Median
$250.00
High
$283.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- Are You Looking for a High-Growth Dividend Stock?zacks.com·Jun 03, 2026
- Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Knowzacks.com·Jun 03, 2026
- Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 studyprnewswire.com·Jun 03, 2026
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's diseaseprnewswire.com·Jun 03, 2026
- Johnson & Johnson (JNJ) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·May 12, 2026
- Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategyzacks.com·May 12, 2026
- Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remissionprnewswire.com·May 07, 2026
- A $2 Million Portfolio Still Has a Safety Trap Most Investors Over 60 Miss247wallst.com·May 04, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $24.06B | $5.24B | $2.14 |
| Q4 Dec 2025 | $24.56B | $5.12B | $2.10 |
| Q3 Sep 2025 | $23.99B | $5.15B | $2.12 |
| Q2 Jun 2025 | $23.74B | $5.54B | $2.29 |
| Q1 Mar 2025 | $21.89B | $11B | $4.54 |
| Q4 Dec 2024 | $22.52B | $3.43B | $1.41 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Decker Robert J officer: VP Corporate Controller | Sell | 4,075 | $1.01M | Feb 27, 2026 |
Schmid Timothy officer: EVP, WW Chair, MedTech | Sell | 1,322 | $324.76K | Feb 20, 2026 |
Schmid Timothy officer: EVP, WW Chair, MedTech | Sell | 13,625 | $3.33M | Feb 18, 2026 |
Schmid Timothy officer: EVP, WW Chair, MedTech | Sell | 8,998 | $2.2M | Feb 18, 2026 |
REED JOHN C officer: EVP, Innovative Medicine, R&D | Sell | 2,283 | $554.77K | Feb 17, 2026 |
Wolk Joseph J officer: Exec VP, CFO | Sell | 24,961 | $6.06M | Feb 17, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $94.19B | $25.6B | $26.8B | $11.03 | +28.46% |
| FY 2024 | $88.82B | $22.15B | $14.07B | $5.79 | +15.84% |
| FY 2023 | $85.16B | $23.41B | $35.15B | $13.72 | +41.28% |
| FY 2023 | $79.99B | $21.01B | $17.94B | $6.73 | +22.43% |
| FY 2022 | $78.74B | $20.94B | $20.88B | $7.81 | +26.52% |